In summary, we used a highly specific antibody coupled with an unbiased set of detection platforms enabled by mass cytometry to parse out CEACAM1 expression in fine detail on human immune cells in healthy donor controls and melanoma and in relation to other immune checkpoint markers. This evidence concerns the gene CEACAM1 and melanoma.